China · Delayed Price · Currency is CNY BeBetter Med Company Description
BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for tumors, autoimmune diseases, and metabolic diseases.
It is developing BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; BEBT-209, a CDK4 highly selective CDK4/6 inhibitor for antitumor; BEBT-109, a pan-mutant EGFR inhibitor for antitumor; BEBT-260, a ChK1 inhibitor for antitumor; BEBT-305, a second-generation HSP90 inhibitor for autoimmune disease; BEBT-503, a pan-PPAR agonist for metabolic disease; BEBT-607, a KRAS G12C inhibitor for antitumor; BEBT-808, an oral small molecule GLP-1R full agonist for metabolic disease; BEBT-809, a GPR75 pathway inhibitor for metabolic disease; and BEBT-508, a small nucleic acid drug.
The company was founded in 2012 and is based in Guangzhou, China.
| Country | China |
| Founded | 2012 |
| Industry | Pharmaceutical Preparations |
| CEO | Changgeng Qian |
Contact Details
Address: 25 Yayingshi Road Guangzhou, 510663 China | |
| Phone | 86 20 3203 8087 |
| Website | bebettermed.cn |
Stock Details
| Ticker Symbol | 688759 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Changgeng Qian | Chief Executive Officer |
| Tianyi Zhang | Chief Financial Officer |